Clincosm LogoSign in Get a demo

diffuse large b cell lymphoma

Showing 1 - 25 of 206
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Diffuse Large B Cell Lymphoma
  • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Nov 19, 2023

Diffuse Large B Cell Lymphoma Trial in Rouen (Measure of the circulating tumor DNA)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • Measure of the circulating tumor DNA
  • Rouen, France
    Centre Henri Becquerel
Nov 17, 2023

Venetoclax Tablets Crushed and Dissolved Into a Solution

Not yet recruiting
  • Hematologic Malignancy
  • +18 more
  • 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
  • Cincinnati, Ohio
    Cincinnati Children's Hospital Medical Center
Nov 8, 2023

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

Not yet recruiting
  • Non-hodgkin Lymphoma
  • +9 more
  • CD79b-19 CAR T cells
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Sep 6, 2023

Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (ONM-501, Cemiplimab)

Not yet recruiting
  • Triple Negative Breast Cancer
  • +13 more
  • (no location specified)
Aug 29, 2023

Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma Trial in United States (P-CD19CD20-ALLO1, Rimiducid)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • +5 more
  • La Jolla, California
  • +7 more
Aug 25, 2023

Diffuse Large B Cell Lymphoma Trial in Wuhan (Zanubrutinib plus RCHOP)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib plus RCHOP
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Aug 16, 2023

Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma Trial in Boston (Adaptive Bridging Radiation Therapy (ABRT))

Not yet recruiting
  • Lymphoma, B-Cell
  • +7 more
  • Adaptive Bridging Radiation Therapy (ABRT)
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Aug 16, 2023

Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (Pirtobrutinib, LV20.19 CAR T cells)

Not yet recruiting
  • Non Hodgkin Lymphoma
  • +5 more
  • (no location specified)
Aug 4, 2023

Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL

Recruiting
  • Diffuse Large B Cell Lymphoma
    • Salvador, Bahia, Brazil
    • +9 more
    Jul 24, 2023

    Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab Vedotin, Rituximab)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Zanubrutinib, Polatuzumab Vedotin, Rituximab
    • Shanghai, Shanghai, China
      Zhongshan Hospital，Fudan University
    Jul 10, 2023

    Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab vedotin and Rituximab)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • Zanubrutinib, Polatuzumab vedotin and Rituximab
    • Shanghai, Shanghai, China
      Zhongshan Hospital，Fudan University
    Jul 10, 2023

    Follicular Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma Trial in New York (Tazemetostat Pill)

    Not yet recruiting
    • Follicular Lymphoma
    • +3 more
    • Tazemetostat Pill
    • New York, New York
      Weill Cornell Medicine/NewYork-Presbyterian Hospital
    Jun 28, 2023

    Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma Trial (FT596, Cyclophosphamide,

    Withdrawn
    • Diffuse Large B Cell Lymphoma
    • +4 more
    • (no location specified)
    Jun 28, 2023

    (CHANT)Real World Study of Duvelisib in Treatment of

    Not yet recruiting
    • Follicular Lymphoma
    • +5 more
    • (no location specified)
    Jun 20, 2023

    Extranodal Lymphoma or Lymphoma of Rare Pathological Types

    Not yet recruiting
    • Lymphoma
    • +8 more
    • No interventions need to be specified for this study
    • Shanghai, China
      Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
    Jun 15, 2023

    Diffuse Large B Cell Lymphoma Trial in Shenyang (Zanubrutinib, Rituximab, Cyclophosphamide)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • Shenyang, Liaoning, China
      Xing Xiaojing
    Jun 1, 2023

    Hematologic Malignancy, Large B-cell Lymphoma, Acute Lymphoblastic Leukemia Trial in Los Angeles (autologous hematopoietic stem

    Not yet recruiting
    • Hematologic Malignancy
    • +5 more
    • autologous hematopoietic stem cells added to planned CAR T
    • Los Angeles, California
      Cedars-Sinai Medical Center
    May 31, 2023

    Diffuse Large B Cell Lymphoma Trial in Shanghai (BTK inhibitor, PD-1 inhibitor)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • BTK inhibitor
    • PD-1 inhibitor
    • Shanghai, China
      Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
    May 20, 2023

    Diffuse Large B Cell Lymphoma Trial (Venetoclax, Carmustine, Cytarabine)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • (no location specified)
    May 9, 2023

    Frontline of ASCT in High-risk DLBCL

    Recruiting
    • Diffuse Large B Cell Lymphoma
      • Beijing, Beijing, China
        Peking University People's Hospital
      Apr 26, 2023

      Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

      Not yet recruiting
      • Lymphoma, B-Cell
      • +6 more
      • Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)
      • Guayaquil, Guayas, Ecuador
        Instituto Oncológico Nacional Dr. Juan Tanca Marengo
      Apr 27, 2023

      Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)

      Not yet recruiting
      • Relapsed Non-Hodgkin Lymphoma
      • +6 more
      • (no location specified)
      Apr 12, 2023

      Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

      Recruiting
      • Diffuse Large B Cell Lymphoma
      • +3 more
      • Low-Dose Decitabine plus anti-PD-1
      • Beijing, Beijing, China
        ChinaPLAGH
      Apr 18, 2023